Role of anoikis-related gene PLK1 in kidney renal papillary cell carcinoma: a bioinformatics analysis and preliminary verification on promoting proliferation and migration

Background: Kidney renal papillary cell carcinoma (KIRP) is a rare malignancy with a very poor prognosis. Anoikis is a specific form of apoptosis involved in carcinogenesis, but the role of anoikis in KIRP has not been explored. Methods: Anoikis-related genes (ARGs) were obtained from the GeneCards database and Harmonizome database and were used to identify different subtypes of KIRP and construct a prognostic model of KIRP. In addition, we also explored the immune microenvironment and enrichment pathways among different subtypes by consensus clustering into different subtypes. Drug sensitivity analysis was used to screen for potential drugs. Finally, we verified the mRNA and protein expression of the independent prognostic gene PLK1 in patient tissues and various cells and further verified the changes in relevant prognostic functions after constructing a PLK1 stable knockdown model using ShRNA. Results: We identified 99 differentially expressed anoikis-related genes (DEGs) associated with KIRP survival, and selected 3 genes from them to construct a prognostic model, which can well predict the prognosis of KIRP patients. Consensus clustering divided KIRP into two subtypes, and there was a significant difference in survival rates between the two subtypes. Immune profiling revealed differing immune statuses between the two subtypes, and functional analysis reveals the differential activity of different functions in different subtypes. Drug sensitivity analysis screened out 15 highly sensitive drugs in the high-risk group and 11 highly sensitive drugs in the low-risk group. Univariate and multivariate Cox regression analysis confirmed that PLK1 was an independent prognostic factor in KIRP, and its mRNA and protein expression levels were consistent with gene differential expression levels, both of which were highly expressed in KIRP. Functional verification of PLK1 in KIRP revealed significant results. Specifically, silencing PLK1 inhibited cell proliferation, clonogenicity, and migration, which indicated that PLK1 plays an important role in the proliferation and migration of KIRP. Conclusion: The prognosis model constructed by ARGs in this study can accurately predict the prognosis of KIRP patients. ARGs, especially PLK1, play an important role in the development of KIRP. This research can help doctors provide individualized treatment plans for KIRP patients and provide researchers with new research ideas.

[1]  Zhicheng Zhang,et al.  Bioinformatic analysis highlights SNHG6 as a putative prognostic biomarker for kidney renal papillary cell carcinoma , 2023, BMC Urology.

[2]  F. Zhou,et al.  A novel Anoikis and immune-related genes marked prognostic signature for colorectal cancer , 2022, Medicine.

[3]  Zhengjie Zhu,et al.  A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in clear cell renal cell carcinoma , 2022, Frontiers in Genetics.

[4]  P. Barata,et al.  Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials. , 2022, Cancer treatment and research communications.

[5]  Yue Zhao,et al.  A novel anoikis-related gene signature predicts prognosis in patients with head and neck squamous cell carcinoma and reveals immune infiltration , 2022, Frontiers in Genetics.

[6]  Sagar M. Utturkar,et al.  Targeting Plk1 sensitizes pancreatic cancer to immune checkpoint therapy. , 2022, Cancer research.

[7]  Natnaree Siriwon,et al.  Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment , 2022, Nature Communications.

[8]  Fan Wang,et al.  The Protective Mechanism of Afuresertib against Esophageal Cancer , 2022, Disease markers.

[9]  Chengjun Wu,et al.  Bioinformatics Analysis Highlight Differentially Expressed CCNB1 and PLK1 Genes as Potential Anti-Breast Cancer Drug Targets and Prognostic Markers , 2022, Genes.

[10]  Yu Jin,et al.  CDKN3 Overcomes Bladder Cancer Cisplatin Resistance via LDHA-Dependent Glycolysis Reprogramming , 2022, OncoTargets and therapy.

[11]  K. Ouyang,et al.  Identification and Validation of a Ferroptosis-Related Signature for Predicting Prognosis and Immune Microenvironment in Papillary Renal Cell Carcinoma , 2022, International journal of general medicine.

[12]  Yuchao Lu,et al.  Identification and Quantification of Necroptosis Landscape on Therapy and Prognosis in Kidney Renal Clear Cell Carcinoma , 2022, Frontiers in Genetics.

[13]  Yingqing Zhou,et al.  Construction and evaluation of an integrated predictive model for chronic kidney disease based on the random forest and artificial neural network approaches. , 2022, Biochemical and biophysical research communications.

[14]  E. Solary,et al.  CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia , 2022, bioRxiv.

[15]  Wei Zhao,et al.  Bioinformatics analysis of BIRC5 in human cancers , 2022, Annals of translational medicine.

[16]  Lingxiang Liu,et al.  MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A , 2021, Journal of Ovarian Research.

[17]  Xiaochen Sun,et al.  TAGLN Is Downregulated by TRAF6-Mediated Proteasomal Degradation in Prostate Cancer Cells , 2021, Molecular Cancer Research.

[18]  Jie Lin,et al.  A ferroptosis-related gene signature for graft loss prediction following renal allograft , 2021, Bioengineered.

[19]  Lixin Ma,et al.  Integrated Analysis of a Competing Endogenous RNA Network Reveals a Prognostic Signature in Kidney Renal Papillary Cell Carcinoma , 2020, Frontiers in Cell and Developmental Biology.

[20]  Ying Lin,et al.  TAGLN and High-mobility Group AT-Hook 2 (HMGA2) Complex Regulates TGF-β-induced Colorectal Cancer Metastasis , 2020, OncoTargets and therapy.

[21]  Haixiang Shen,et al.  The prognostic value of lncRNA SNHG6 in cancer patients , 2020, Cancer Cell International.

[22]  L. Zhang,et al.  CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1. , 2020, European review for medical and pharmacological sciences.

[23]  O. Güner,et al.  Akt Pathway Inhibitors. , 2020, Current topics in medicinal chemistry.

[24]  H. Moch,et al.  Loss of CDKN1A mRNA and Protein Expression Are Independent Predictors of Poor Outcome in Chromophobe Renal Cell Carcinoma Patients , 2020, Cancers.

[25]  Junhua Zheng,et al.  MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR‐203 and promoting the expression of BIRC5 , 2019, Cell proliferation.

[26]  Zonghui Ding,et al.  Elevated level of mitochondrial reactive oxygen species via fatty acid β-oxidation in cancer stem cells promotes cancer metastasis by inducing epithelial–mesenchymal transition , 2019, Stem Cell Research & Therapy.

[27]  C. Corbet,et al.  Therapeutic Targeting of Cancer Stem Cells: Integrating and Exploiting the Acidic Niche , 2019, Front. Oncol..

[28]  T. A. Al Hussain,et al.  Papillary Renal Cell Carcinoma (PRCC): An Update. , 2019, Advances in anatomic pathology.

[29]  Anas M. Saad,et al.  Trends in Renal‐Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER‐Based Study , 2019, Clinical genitourinary cancer.

[30]  Xiaozhong Peng,et al.  Acidosis enhances the self-renewal and mitochondrial respiration of stem cell-like glioma cells through CYP24A1-mediated reduction of vitamin D , 2019, Cell Death & Disease.

[31]  Yun Liu,et al.  CALD1, CNN1, and TAGLN identified as potential prognostic molecular markers of bladder cancer by bioinformatics analysis , 2019, Medicine.

[32]  F. Grossi,et al.  Afatinib and Erlotinib in the treatment of squamous-cell lung cancer , 2018, Expert opinion on pharmacotherapy.

[33]  Lin-zhong Zhu,et al.  Clinical significance and functions of microRNA‐93/CDKN1A axis in human cervical cancer , 2018, Life sciences.

[34]  R. Cirocchi,et al.  A novel regulatory function of CDKN1A/p21 in TNFα-induced matrix metalloproteinase 9-dependent migration and invasion of triple-negative breast cancer cells. , 2018, Cellular signalling.

[35]  A. Choudhury,et al.  Regulation of Cell Cycle Associated Genes by microRNA and Transcription Factor. , 2017, MicroRNA.

[36]  Andrew D. Rouillard,et al.  The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins , 2016, Database J. Biol. Databases Curation.

[37]  N. Ahmad,et al.  Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics , 2016, Molecular Cancer Therapeutics.

[38]  J. Brower,et al.  Erlotinib for the treatment of brain metastases in non-small cell lung cancer , 2016, Expert opinion on pharmacotherapy.

[39]  Xin Hu,et al.  Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway , 2016, OncoTargets and therapy.

[40]  X. Guan,et al.  Cancer metastases: challenges and opportunities , 2015, Acta pharmaceutica Sinica. B.

[41]  E. Nigg,et al.  Plk1 and Mps1 Cooperatively Regulate the Spindle Assembly Checkpoint in Human Cells. , 2015, Cell reports.

[42]  A. Długosz,et al.  Preliminary Study on J-Resolved NMR Method Usability for Toxic Kidney's Injury Assessment. , 2015, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[43]  J. Lopes,et al.  Pathology, therapy and prognosis of papillary renal carcinoma. , 2015, Future oncology.

[44]  J. Berumen,et al.  Targeting CDKN3 in cervical cancer , 2014, Expert opinion on therapeutic targets.

[45]  A. Weinberg,et al.  Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology , 2014, International Urology and Nephrology.

[46]  K. Strebhardt,et al.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy , 2010, Nature Reviews Drug Discovery.

[47]  M. Savio,et al.  Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. , 2010, Mutation research.

[48]  Jan-Michael Peters,et al.  Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle. , 2007, Developmental cell.

[49]  E Ruoslahti,et al.  Integrins and anoikis. , 1997, Current opinion in cell biology.

[50]  Rensheng Wang,et al.  Identification of a tumor microenvironment-associated prognostic gene signature in bladder cancer by integrated bioinformatic analysis. , 2021, International journal of clinical and experimental pathology.

[51]  N. Kyprianou,et al.  Anoikis and EMT: Lethal "Liaisons" during Cancer Progression. , 2016, Critical reviews in oncogenesis.

[52]  A. Gilmore,et al.  Anoikis. , 2000, Cell death and differentiation.